<DOC>
	<DOCNO>NCT00004641</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate efficacy certain drug prevent intestinal complication patient cirrhosis high blood pressure hepatic portal vein . II . Evaluate vein pressure measurement predict development internal bleeding .</brief_summary>
	<brief_title>A Study Prevent Complications High Blood Pressure Caused Hepatitis Patients With Cirrhosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double-blind study . Patients stratify participate institution , cirrhosis etiology , hepatic venous pressure gradient . The dose oral timolol titrate 28 day . Patients randomly assign daily timolol titrate dose placebo successful titration achieve day 28 , final titration dose maintain least 10 day . Timolol discontinue prior randomization . Criteria removal study include esophageal gastric varix , significant bleeding hemorrhage , timolol-induced hepatic encephalopathy , liver transplantation . Patients follow every 3 month .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Esophageal Gastric Varices</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Biopsyproven cirrhosis etiology , include hepatitis B C. No primary biliary cirrhosis . Hepatic venous pressure gradient ( HVPG ) least 6 mm Hg . Histologic slide available review OR liverspleen scan compatible cirrhosis biopsy old 5 year . Repeat biopsy require scan incompatible OR HVPG least 10 mm Hg follow clinical feature suggestive cirrhosis : telangiectasias , palmar erythema , muscle wasting , liver hard nodular , splenomegaly , hypoalbuminemia , hyperbilirubinemia , prolong prothrombin time , liverspleen scan colloid shift spleen bone marrow , collateral visualize ultrasound CT. Gastroesophageal varix negative endoscopy within 3 month prior randomization . Independent verification 2 endoscopists require . No ascites require specific treatment , e.g. , diuretic , paracentesis , peritoneovenous shunt . Ascites control salt restriction alone allow . No splenic portal vein thrombosis Dopplerultrasound . No primary sclerosing cholangitis . No radiologically histologically proven hepatocellular carcinoma . Prior/Concurrent Therapy At least 1 month since participation another pharmacologic clinical trial . At least 1 month since drug may affect splanchnic hemodynamics portal pressure , e.g. , betablockers , clonidine prazosin , nitrate molsidomine Patient Characteristics Life expectancy : At least 1 year Other : Eligibility determine individual basis follow : aortic valve stenosis , atrioventricular block , asthma , chronic obstructive pulmonary disease positive bronchoconstrictive test , heart failure , hypersensitivity betablockers , insulindependent diabetes , organic psychosis , peripheral vascular disease . No alcohol intake titration period . No pregnant woman . Effective contraception require fertile woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Cruveilhier-Baumgarten Syndrome</keyword>
	<keyword>Esophageal Varices</keyword>
	<keyword>Gastric Varices</keyword>
	<keyword>Esophageal Varix</keyword>
	<keyword>Gastric Varix</keyword>
	<keyword>Alcoholic Cirrhosis</keyword>
</DOC>